CAJ | 학술논문

目的观察玻璃体腔注射抗血管内皮生长因子单克隆抗体ranibizumab(商品名:Lucentis)治疗特发性脉络膜新生血管(ICNV)的近期临床疗效.方法回顾性无对照研究.将2011年8月至2014年1月,在武汉大学人民医院眼科中心就诊的ICNV患者15例15只眼纳入研究.测量最佳矫正视力(BCVA),行眼压、检眼镜、眼底照相、荧光素眼底血管造影(FFA)及光相干断层扫描(OCT)检查.视力转化为标准化log MAR视力进行计算.治疗前平均BCVA为(0.72±0.51) logMAR;黄斑中心凹视网膜厚度(CMT) 202～437 μm,平均(309.60±59.58) μm.所有患眼玻璃体腔注射10 mg/ml ranibizumab 0.05 ml(含ranibizumab 0.5 mg).治疗后第1、2、3、6个月各随访1次,对比分析治疗前后BCVA及CMT变化情况.结果末次随访时,所有患眼平均玻璃体腔注射(1.80±1.01)次,矫正视力较治疗前提高(0.37±0.55) log MAR,差异有统计学意义(t=2.611,P＜0.05);CMT降低(76.80±58.73) μm,差异有统计意义(t=5.065,P＜0.05).随访期间未发现与治疗相关的全身及眼部并发症.结论玻璃体腔注射ranibizumab治疗特发性脉络膜新生血管视力预后较好,病灶水肿消退明显,安全性高.
목적 관찰파리체강주사항혈관내피생장인자단극륭항체ranibizumab(상품명:Lucentis)치료특발성맥락막신생혈관(ICNV)적근기림상료효.방법 회고성무대조연구.장2011년8월지2014년1월,재무한대학인민의원안과중심취진적ICNV환자15례15지안납입연구.측량최가교정시력(BCVA),행안압、검안경、안저조상、형광소안저혈관조영(FFA)급광상간단층소묘(OCT)검사.시력전화위표준화log MAR시력진행계산.치료전평균BCVA위(0.72±0.51) logMAR;황반중심요시망막후도(CMT) 202～437 μm,평균(309.60±59.58) μm.소유환안파리체강주사10 mg/ml ranibizumab 0.05 ml(함ranibizumab 0.5 mg).치료후제1、2、3、6개월각수방1차,대비분석치료전후BCVA급CMT변화정황.결과 말차수방시,소유환안평균파리체강주사(1.80±1.01)차,교정시력교치료전제고(0.37±0.55) log MAR,차이유통계학의의(t=2.611,P＜0.05);CMT강저(76.80±58.73) μm,차이유통계의의(t=5.065,P＜0.05).수방기간미발현여치료상관적전신급안부병발증.결론 파리체강주사ranibizumab치료특발성맥락막신생혈관시력예후교호,병조수종소퇴명현,안전성고.
Objective To observe the safety and efficacy of intravitreal injection of ranibizumab for the treatment of idiopathic choroidal neovascularization (ICNV).Methods Fifteen patients with ICNV were included in this retrospective,uncontrolled clinical trial.Their eyes were treated with a single intravitreal injection of 0.5 mg ranibizumab at the first time,and then followed by dosing as needed (pro re nata [PRN]) at every follow-up visit at month 1,2,3,6.The inspection findings of best-corrected visual acuity (BCVA),intraocular pressure,ophthalmoscope,fundus photography,fundus fluorescein angiography (FFA) and optical coherence tomography (OCT) before treatment and at every follow-up visit were observed and analyzed.The average BCVA was (0.72±0.51) log MAR in the baseline; the central macular thickness (CMT) was 202-437μm,the average value was (309.60± 59.58)μm.The changes of BCVA,CMT before and after treatment were observed.Results At the last follow-up,the mean intravitreal injection of ranibizumab of all the eyes was (1.80±1.01) times,the BCVA improved (0.37±0.55) log MAR,the difference was statistically significant (t =2.611,P ＜ 0.05); CMT decreased (76.80±58.73)μm,the difference was statistically significant (t =5.065,P ＜ 0.05).No ocular or systemic adverse events were found after intravitreal injection of ranibizumab during the follow-up duration.Conclusions Intravitreal injection of ranibizumab,which can improve the visual acuity,reduce the macular edema,showed a promising efficacy and safety profile in the treatment of ICNV.